Jan 04, 2024 / 05:45PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
I suspect that people are going to be strolling in, but I don't like to penalize people who are on time. And let's try to stay on time, so let's get underway here.
Welcome to what is, by definition, in my opinion, the keynote presentation of this conference. We are thrilled to have Merck, in particular, Chief Executive Officer, Rob Davis, who is back for a second consecutive year. And we're going to make this an annual tradition. Peter promises me this. He didn't, but I just put the words in his mouth.
So Rob Davis, thank you so much for joining us; and Peter Dannenbaum, the esteemed Investor Relations head and -- who's with us for this conversation here.
Chris Shibutani, member of the Goldman Sachs research team for the health care group. So Rob, I hope you are ready to once again kick off this year providing voice for Merck as we start.
Questions and Answers:
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research AnalystAnd
Trustpilot
